Study of Water- and Organic-Soluble Extracts from on Type 1 Diabetes Mellitus

Overview

Journal J Diabetes Res

Publisher Wiley

Specialty Endocrinology

Date 2022 Feb 28

PMID 35224106

Authors

Bo Zhang

Yanli Yuan

Jie Xin

Min Chen

Zhen Wang

Xinpeng Li

Tao Xue

Affiliations

Soon will be listed here.

Abstract

This study investigates the effects of the water-soluble and organic-soluble extracts on the hyperglycemic condition in streptozotocin- (STZ-) induced diabetic rats. The blood glucose levels, body weights, water intake, and urine volumes of rats in different experimental groups were monitored throughout the experiment, and the results obtained indicate that the two extracts can effectively reduce blood sugar levels, increase body weights, and improve water intake and urine volumes in diabetic rats. Based on blood biochemical analyses, the two extracts play an important role in regulating the diabetes-induced lipid metabolism disorder, increasing the levels of insulin and C-peptide, and alleviating the symptoms of diabetes. The variation in the liver glycogen contents of the water-soluble fraction and ethanol fraction groups suggests that the mechanisms underlying the hypoglycemic effects of the two extracts are different. Indeed, the water-soluble fraction alleviates diabetes symptoms in rats mainly by antioxidative activity, unlike the ethanol fraction.

References

Stabler C, Li Y, Stewart J, Keselowsky B . Engineering immunomodulatory biomaterials for type 1 diabetes. Nat Rev Mater. 2020; 4(6):429-450. PMC: 7332200. DOI: 10.1038/s41578-019-0112-5. View

Livingstone S, Levin D, Looker H, Lindsay R, Wild S, Joss N . Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015; 313(1):37-44. PMC: 4426486. DOI: 10.1001/jama.2014.16425. View

Katsarou A, Gudbjornsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson B . Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017; 3:17016. DOI: 10.1038/nrdp.2017.16. View

Pescovitz M, Greenbaum C, Bundy B, Becker D, Gitelman S, Goland R . B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care. 2013; 37(2):453-9. PMC: 3898764. DOI: 10.2337/dc13-0626. View

Atkinson M, Roep B, Posgai A, Wheeler D, Peakman M . The challenge of modulating β-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2018; 7(1):52-64. PMC: 7322790. DOI: 10.1016/S2213-8587(18)30112-8. View

Aronson R, Gottlieb P, Christiansen J, Donner T, Bosi E, Bode B . Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014; 37(10):2746-54. PMC: 4392937. DOI: 10.2337/dc13-0327. View

Roep B, Thomaidou S, van Tienhoven R, Zaldumbide A . Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 2020; 17(3):150-161. PMC: 7722981. DOI: 10.1038/s41574-020-00443-4. View

Yin J, Yang L, Mou L, Dong K, Jiang J, Xue S . A green tea-triggered genetic control system for treating diabetes in mice and monkeys. Sci Transl Med. 2019; 11(515). DOI: 10.1126/scitranslmed.aav8826. View

Buzzetti R, Zampetti S, Maddaloni E . Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017; 13(11):674-686. DOI: 10.1038/nrendo.2017.99. View

10.

Scott L, Erdos M, Huyghe J, Welch R, Beck A, Wolford B . The genetic regulatory signature of type 2 diabetes in human skeletal muscle. Nat Commun. 2016; 7:11764. PMC: 4931250. DOI: 10.1038/ncomms11764. View

11.

Li D, Yue Q, Liu L, Che K, Liu X, Hu C . Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats. Acta Pharmacol Sin. 2021; 42(8):1267-1279. PMC: 8285380. DOI: 10.1038/s41401-021-00680-x. View

12.

Miura A, Hosono T, Seki T . Macrophage potentiates the recovery of liver zonation and metabolic function after acute liver injury. Sci Rep. 2021; 11(1):9730. PMC: 8102573. DOI: 10.1038/s41598-021-88989-9. View

13.

Okun J, Rusu P, Chan A, Wu Y, Yap Y, Sharkie T . Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes. Nat Metab. 2021; 3(3):394-409. DOI: 10.1038/s42255-021-00369-9. View

14.

Orban T, Bundy B, Becker D, DiMeglio L, Gitelman S, Goland R . Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011; 378(9789):412-9. PMC: 3462593. DOI: 10.1016/S0140-6736(11)60886-6. View

15.

Patterson C, Gyurus E, Rosenbauer J, Cinek O, Neu A, Schober E . Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase. Diabetologia. 2012; 55(8):2142-7. DOI: 10.1007/s00125-012-2571-8. View

16.

Buzzetti R, Cernea S, Petrone A, Capizzi M, Spoletini M, Zampetti S . C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study. Diabetes. 2011; 60(11):3067-72. PMC: 3198071. DOI: 10.2337/db10-0560. View

17.

Dai X, Jiang P, Ji Y, Zhu X, Sun X . Suppression of murine B-cell lymphoma growth by trichosanthin through anti-angiogenesis. Am J Transl Res. 2019; 11(6):3567-3577. PMC: 6614629. View

18.

Zhang C, Fennel E, Douillet C, Styblo M . Exposures to arsenite and methylarsonite produce insulin resistance and impair insulin-dependent glycogen metabolism in hepatocytes. Arch Toxicol. 2017; 91(12):3811-3821. PMC: 6611171. DOI: 10.1007/s00204-017-2076-9. View

19.

Hober D, Alidjinou E . Diabetes: Towards a coxsackievirus B-based vaccine to combat T1DM. Nat Rev Endocrinol. 2018; 14(3):131-132. DOI: 10.1038/nrendo.2017.184. View

20.

Xu J, Wang Y, Wang Z, Guo L, Li X . Fucoidan mitigated diabetic nephropathy through the downregulation of PKC and modulation of NF-κB signaling pathway: in vitro and in vivo investigations. Phytother Res. 2020; 35(4):2133-2144. DOI: 10.1002/ptr.6966. View